The Board of Directors and I are confident in his ability to lead Gilead
into the future," said Dr.
The funds raised through the issue will be funnelled into Gilead
's takeover of viral infection therapies developer Pharmasset Inc (NASDAQ:VRUS).
products are in late-stage clinical development and consist of Elvitegravir, an investigational integrase inhibitor; Cobicistat, an investigational antiretroviral (ARV) boosting agent; and the "Quad," a once-daily, single-tablet combination of four separate Gilead
In March 2002, Gilead
announced the initiation of an early access program in the United States to provide adefovir dipivoxil to chronic hepatitis B patients with lamivudine-resistant HBV.
did test tenofovir first in late-stage patients, and if it is punished with a restrictive label, other companies will become even more reluctant to test early for advanced patients, who need new options the most.
Canada is pleased that Ontario will provide access to new treatment options that help address the evolving needs of a range of people living with HIV,' said Kennet Brysting, Vice President and General Manager, Gilead
Galapagos will receive a USD 3.95 bn upfront payment and a USD 1.1bn equity investment from Gilead
. Galapagos will use the proceeds to expand and accelerate its research and development programs.
Capital pursues a Leadership Investing strategy, supporting its portfolio companies by constructively engaging with management teams and boards of directors to elevate governance and enhance long-term value for the benefit of all shareholders.??
(Alliance News) - Biopharmaceutical company Gilead
Sciences Inc and biotechnology firm Galapagos NV on Monday reported the closing of the global research & development collaboration agreement, signed in mid-July.
"I am very pleased with Gilead
's performance and our ability to continue to reach patients around the world with our medicines.
Under the agreement, Gilead
will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets.
- US-based biopharmaceutical company Gilead
Durect (DRRX) announced that it has entered into an agreement with Gilead
(GILD) granting Gilead
the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER technology.
Sciences, Inc., today, announced that it has become an official partner of the 2019 Africa Cup of Nations - Africa's biggest football competition.